Astressin Platform
Irritable Bowel Syndrome (IBS)
Key Facts
About Sentia Medical Sciences
Sentia Medical Sciences is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is pioneering a novel therapeutic approach to chronic stress by developing astressins, peptide antagonists that block CRF receptors, aiming to re-establish biological homeostasis. Its pipeline targets significant unmet needs in gastrointestinal motility disorders like IBS, gastroparesis, and postoperative ileus, as well as endocrine conditions like Congenital Adrenal Hyperplasia. Sentia's core technology is exclusively licensed from the Salk Institute and is distinguished by its potential for long-acting effects and a favorable safety profile observed in preclinical models.
View full company profileAbout Sentia Medical Sciences
Sentia Medical Sciences is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is pioneering a novel therapeutic approach to chronic stress by developing astressins, peptide antagonists that block CRF receptors, aiming to re-establish biological homeostasis. Its pipeline targets significant unmet needs in gastrointestinal motility disorders like IBS, gastroparesis, and postoperative ileus, as well as endocrine conditions like Congenital Adrenal Hyperplasia. Sentia's core technology is exclusively licensed from the Salk Institute and is distinguished by its potential for long-acting effects and a favorable safety profile observed in preclinical models.
View full company profileAbout Sentia Medical Sciences
Sentia Medical Sciences is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is pioneering a novel therapeutic approach to chronic stress by developing astressins, peptide antagonists that block CRF receptors, aiming to re-establish biological homeostasis. Its pipeline targets significant unmet needs in gastrointestinal motility disorders like IBS, gastroparesis, and postoperative ileus, as well as endocrine conditions like Congenital Adrenal Hyperplasia. Sentia's core technology is exclusively licensed from the Salk Institute and is distinguished by its potential for long-acting effects and a favorable safety profile observed in preclinical models.
View full company profileAbout Sentia Medical Sciences
Sentia Medical Sciences is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is pioneering a novel therapeutic approach to chronic stress by developing astressins, peptide antagonists that block CRF receptors, aiming to re-establish biological homeostasis. Its pipeline targets significant unmet needs in gastrointestinal motility disorders like IBS, gastroparesis, and postoperative ileus, as well as endocrine conditions like Congenital Adrenal Hyperplasia. Sentia's core technology is exclusively licensed from the Salk Institute and is distinguished by its potential for long-acting effects and a favorable safety profile observed in preclinical models.
View full company profileAbout Sentia Medical Sciences
Sentia Medical Sciences is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is pioneering a novel therapeutic approach to chronic stress by developing astressins, peptide antagonists that block CRF receptors, aiming to re-establish biological homeostasis. Its pipeline targets significant unmet needs in gastrointestinal motility disorders like IBS, gastroparesis, and postoperative ileus, as well as endocrine conditions like Congenital Adrenal Hyperplasia. Sentia's core technology is exclusively licensed from the Salk Institute and is distinguished by its potential for long-acting effects and a favorable safety profile observed in preclinical models.
View full company profileAbout Sentia Medical Sciences
Sentia Medical Sciences is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is pioneering a novel therapeutic approach to chronic stress by developing astressins, peptide antagonists that block CRF receptors, aiming to re-establish biological homeostasis. Its pipeline targets significant unmet needs in gastrointestinal motility disorders like IBS, gastroparesis, and postoperative ileus, as well as endocrine conditions like Congenital Adrenal Hyperplasia. Sentia's core technology is exclusively licensed from the Salk Institute and is distinguished by its potential for long-acting effects and a favorable safety profile observed in preclinical models.
View full company profileTherapeutic Areas
Other Irritable Bowel Syndrome (IBS) Drugs
| Drug | Company | Phase |
|---|---|---|
| inFoods® IBS | Biomerica | FDA PMA Clinical Study |